Ionis Pharmaceuticals (NASDAQ:IONS) will announce its earnings results before the market opens on Monday, February 26th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Shares of Ionis Pharmaceuticals (NASDAQ IONS) opened at $50.05 on Monday. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. The stock has a market capitalization of $6,250.00, a P/E ratio of 357.50 and a beta of 2.53. Ionis Pharmaceuticals has a 12 month low of $37.26 and a 12 month high of $65.51.
In related news, CFO Elizabeth L. Hougen sold 2,724 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $51.76, for a total transaction of $140,994.24. Following the transaction, the chief financial officer now owns 17,224 shares in the company, valued at $891,514.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Elizabeth L. Hougen sold 4,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $57.00, for a total value of $228,000.00. Following the transaction, the senior vice president now owns 14,392 shares in the company, valued at approximately $820,344. The disclosure for this sale can be found here. In the last quarter, insiders have sold 124,635 shares of company stock worth $6,482,681. 2.13% of the stock is currently owned by company insiders.
A hedge fund recently raised its stake in Ionis Pharmaceuticals stock. The Manufacturers Life Insurance Company increased its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 9.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,744 shares of the company’s stock after buying an additional 311 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Ionis Pharmaceuticals were worth $190,000 at the end of the most recent reporting period. 91.40% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on IONS. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target on the stock in a research note on Friday, October 27th. BMO Capital Markets lifted their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Morgan Stanley lifted their price target on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. Finally, BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $50.76.
ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals (IONS) to Release Quarterly Earnings on Monday” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/ionis-pharmaceuticals-ions-to-release-quarterly-earnings-on-monday-2.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.